Institutional members access full text with Ovid®

Share this article on:

Current Applications and Safety of Autologous Fat Grafts: A Report of the ASPS Fat Graft Task Force

Gutowski, Karol A. M.D.ASPS Fat Graft Task Force

Plastic and Reconstructive Surgery: July 2009 - Volume 124 - Issue 1 - p 272-280
doi: 10.1097/PRS.0b013e3181a09506
Cosmetic: Special Topics
Related Blogs

Task Force Statement: In 2007, the American Society of Plastic Surgeons formed a task force to conduct an assessment regarding the safety and efficacy of autologous fat grafting, specifically to the breast, and to make recommendations for future research. The task force formulated specific issues regarding fat grafting and then compiled them to focus on five broad-based questions:

What are the current and potential applications of fat grafting (specifically breast indications, and if data are available, other cosmetic and reconstructive applications)?What risks and complications are associated with fat grafting?How does technique affect outcomes, including safety and efficacy, of fat grafting?What risk factors need to be considered for patient selection at this level of invasiveness?What advancements in bench research/molecular biology potentially impact current or future methods of fat grafting? To answer these questions, the task force reviewed the scientific literature, critically appraised the information available, and developed evidence-based practice recommendations. Although the primary issue of interest was fat grafting to the breast, other aspects of fat grafting were evaluated.

Evanston, Ill.

The members of the task force and their affiliations are listed in an Appendix at the end of this article.

Received for publication October 30, 2008; accepted February 10, 2009.

Disclosures:Dr. Gutowski, who was chairman of the tast force, serves as a paid advisor to AestheTec, a company that is developing fat grafting technology; however, he did not hold this position during the activities of the task force. Dr. Coleman receives a royalty for instruments sold by Byron Medical, Beacon, and Mentor; is a medical advisor and has stock or the potential for stock options with Cytori Therapeutics, Zeltiq (unpaid), and Beacon Medical (unpaid); and is an unpaid consultant for the Armed Forces Institute of Regenerative Medicine. Dr. Rubin receives research support from Pfizer, Covidien, and Toucan Capital. The other authors have no financial interests related to fat grafting. No other members of the task force have financial interests related to fat grafting.

Supplemental digital content is available for this article. A direct URL citation appears in the printed text; simply type the URL address into any web browser to access this content. A clickable link to the material is provided in the HTML text of this article on the Journal’s Web site (

Karol A. Gutowski, M.D., 2650 Ridge Avenue, Walgreen Building, Room 2507, Evanston, Ill. 60201,

©2009American Society of Plastic Surgeons